The anti-HER2/HER2 BsAbs KN026 and ZN25 are evaluated in a phase 1 trial (HER2-amplified breast and gastric cancer) and in a phase 2 trial (biliary tract cancer) (45–47). This evidence concerns the gene ERBB2 and biliary tract cancer.